Stroke/Cerebrovascular Disease Perspective

 
 
  • Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
  • Dec 15 2023 This Week in Cardiology   FDA approves PFA, breakthrough in PAH, residual leaks after percutaneous LAAO, OAC in low-intermediate risk people are the topics John Mandrola, MD, discusses in this week’s podcast.
  • The Top Cardiology Trials of 2023   For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.
  • How to Prescribe Zepbound Recently approved tirzepatide joins semaglutide as an option for patients with obesity. Beverly Tchang, MD, offers her recommendations based on her experience for prescribing.
  • Dec 08 2023 This Week in Cardiology   Three aspects of the recent AF guideline documents and a possible new treatment of POTS are the topics John Mandrola, MD, discusses in this week's podcast.
  • Semaglutide Reduces Cardio Risk in Obesity Without Diabetes   Anne Peters discusses recent data on semaglutide and cardiovascular outcomes in patients with preexisting cardiovascular disease and obesity, but with no history of diabetes.
  • How Do We Address the Epidemic of Loneliness and Isolation? The US surgeon general proposed a national strategy to promote social connection and combat loneliness.
  • Dec 01 2023 This Week in Cardiology   More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
  • How Low Should You Go? Is Very Low LDL-C Safe? Drs Connie Newman and Seth Martin highlight the evidence supporting the safety of very low LDL-C levels, and how maintaining low levels protects against CV events such as MI and stroke.
  • Fall Updates in Dementia, PD, and Stroke   Christoph Diener discusses interesting neurology studies published in October, spanning hearing loss and cognitive impairment, Parkinson's disease, and stroke.
  • An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Recommendations This review highlights the current state of Lipoprotein(a), including updates from clinical trial outcomes and guideline recommendations supporting once-in-a-lifetime measurement in most individuals with increased risk of atherosclerotic CVD.
  • To Anticoagulate or Not in Subclinical AF   John Mandrola and ARTESiA investigator Jeff Healey discuss the results and how they compare with the NOAH-AFNET-6 data on the use of DOACs in patients with short-duration AF.
  • Nov 17 2023 This Week in Cardiology   An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week’s podcast.
  • A Better Way to Control Blood Pressure Follow the example of a primary care practice in Ohio that has successfully achieved > 90% blood pressure control in its patients with hypertension.
  • The Future of Medicine Is RNA   Short interfering RNA drugs could be the next big game changers in pharmacotherapeutics.
  • Is It Time for Cardiologists to Treat Obesity?   Cardiologists Michelle O'Donoghue and Nicholas Marston discuss the "game changer" trial at AHA showing that GLP-1 agonist semaglutide reduced CV events in patients with ASCVD and overweight/obesity.
  • Maternal Perinatal Mortality: A Pediatric Issue Dr Barbara Howard "recently become aware of new data that changes my ideas about what we pediatricians need to be doing as part of our care for children and their families."
  • My Pet Peeves About the Current State of Primary Care I know some of these are issues that you all struggle with and I wanted to give a voice to them. I wish I had answers to fix them.
  • AHA 2023 Positive Results From SELECT Begins a New Era in Cardiology The GLP-1 agonist lowered cardiovascular events in overweight patients with CVD. While questions remain on how it works, this cardiologist sees this as a call to change societal norms around obesity.
  • Nov 10 2023 This Week in Cardiology   Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.